Assessment Status | Awaiting HTA submission from Applicant |
HTA ID | 22044 |
Drug | Tisagenlecleucel |
Brand | Kymriah® |
Indication | For the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. |
Assessment Process | |
Rapid review commissioned | 28/06/2022 |
Rapid review completed | 27/07/2022 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE | 31/08/2022 |
Pre-submission consultation with Applicant | 06/12/2022 |